Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 3
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement (recurred) on everolimus and exemestane hormone therapy. Everolimus is a chemotherapy drug that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are hormones that can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by lowering the amount of estrogen and progesterone the body makes. Giving everolimus with a different type of hormone therapy may be an effective treatment for breast cancer in patients who progressed on everolimus with exemestane.
详细描述
PRIMARY OBJECTIVE:
Progression free survival in patients with advanced or metastatic breast cancer receiving everolimus plus hormonal therapy beyond first progression.
SECONDARY OBJECTIVES:
- Clinical benefit rate (sum of stable disease, partial response, complete response).
- Response rate (partial response and complete response).
- Overall survival.
- Safety, side effects and tolerability profile of everolimus.
OUTLINE:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Estrogen (ER) and/or progesterone (PR)-positive at primary diagnosis and at metastatic diagnosis where tissue is available (defined as > or = 1% of staining nuclei)
- •Progressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimus
- •Human epidermal growth factor receptor 2 (HER2)/neu-negative breast cancer by standard criteria (immunohistochemistry [IHC] < 3+ or fluorescence in situ hybridization [FISH] negative if IHC 2+) at primary diagnosis
- •Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
- •Life expectancy > 6 months
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Absolute neutrophil count (ANC) > 1,500/µL
- •Platelets ≥ 100,000/µL
- •Hemoglobin > 10 g/dL
- •Creatinine ≤ 1.5 x upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 x ULN
- •International normalized ratio ≤ 1.3 (or ≤ 3 on anticoagulants)
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
- •Signed informed consent
- •Adequate birth control
- •Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN; NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication
排除标准
- •Prior treatment with everolimus other than in combination with hormonal therapy for treatment of breast cancer or prior treatment with another mammalian target of rapamycin (mTOR) inhibitor (sirolimus, temsirolimus) for any indication
- •HER2 positive disease as defined by 3+ IHC or positive FISH (both in primary and metastatic sites)
- •Active infection: temperature > 100 Fahrenheit (F), fever of unknown origin, active symptoms or signs of infection as defined by the investigator
- •Uncontrolled central nervous system metastases
- •Life-threatening, visceral metastases
- •Pregnant or lactating women
- •Prior chemotherapy within the last 4 weeks
- •Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
- •Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- •History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias
- •Hypersensitivity to trial medications (everolimus)
- •Emotional limitations, which the investigator judges could limit the patient's ability to follow up and comply with study procedures
- •Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
- •Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN
- •Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
- •A known history of human immunodeficiency virus (HIV) seropositivity
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of EVEROLIMUS (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- •Patients with an active, bleeding diathesis
- •Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)
- •Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest
- •Taking any of the following agents:
- •Chronic treatment with systemic steroids or another immunosuppressive agent (use of steroids as part of management of everolimus toxicities will be allowed)
- •Live vaccines
- •Patients who have received live attenuated vaccines within 1 week of start of everolimus and during the study; patient should also avoid close contact with others who have received live attenuated vaccines; examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, bacillus Calmette-Guérin (BCG), yellow fever, varicella and TY21a typhoid vaccines
- •Drugs or substances known to be inhibitors or inducers of the isoenzyme cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A)
研究组 & 干预措施
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: everolimus (Drug)
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: anastrozole (Drug)
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: letrozole (Drug)
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: tamoxifen citrate (Drug)
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: fulvestrant (Drug)
Treatment (everolimus, hormone therapy)
Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
干预措施: megestrol acetate (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: Up to 2 years
Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.
Response Rate (Partial Response Plus Complete Response) Using RECIST
时间窗: Up to 2 years
Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.
次要结局
- Clinical Benefit Rate (Response Rate Plus Stable Disease)(Up to 2 years)
- Overall Survival (OS)(From the initiation of alternate hormonal treatment in combination with everolimus to time of death from any cause, assessed up to 2 years)
- Incidence of Adverse Events Assessed Using Common Terminology Criteria for Adverse Events Version 4.0(Up to 2 years)
研究者
Suchita Pakkala
Principal Investigator
Emory University